Terapia Intensiva

Hipertensão intra-abdominal e síndrome compartimental abdominal em pacientes criticamente doentes: uma revisão do passado, do presente e dos passos futuros.

5 Out, 2021 | 11:16h

Intra-abdominal hypertension and abdominal compartment syndrome in critically ill patients: A narrative review of past, present, and future steps – Scandinavian Journal of Surgery

Revisão | Aprimoramento do cuidado de idosos criticamente doentes.

5 Out, 2021 | 11:15h

Optimizing care for critically ill older adults – Canadian Medical Association Journal

[Comunicado de imprensa – ainda não publicado] Merck anuncia que o antiviral oral Molnupiravir reduziu o risco de internação ou morte em cerca de 50%, comparado ao placebo, em pacientes com COVID-19 leve ou moderada.

4 Out, 2021 | 10:38h

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

Comentários:

Expert reaction to interim analysis of oral antiviral molnupiravir – Science Media Centre

Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment – STAT

Covid antiviral pill can halve risk of hospitalization – BBC

Why Merck’s Covid-19 pill molnupiravir could be so important – Vox

‘Unquestionably a game changer!’ Antiviral pill cuts COVID-19 hospitalization risk – Researchers excited about Merck drug, but caution data are preliminary and price is high – Science

Comentários no Twitter

.@DrEricDing convinced many that stopping the #molnupiravir trial early for benefit was a good idea

But it was NOT

Large body of evidence suggests that stopping early for benefit biases the results: overestimates the benefits of the treatment #EBM https://t.co/b3tHEtliO0 https://t.co/LwuCgqcY0C pic.twitter.com/vyPWc0nd37

— Kari Tikkinen (@KariTikkinen) October 2, 2021

(fio – clique para saber mais)

💡BREAKING—New oral anti-viral drug *molnupiravir* cuts risk of #COVID19 hospitalization and death **in HALF** in a randomized trial. Results so astounding that the trial is being stopped early, and Merck plans to apply for emergency authorization ASAP. 🧵 https://t.co/g8JGNzvuRg pic.twitter.com/K1SwC3QFXS

— Eric Feigl-Ding (@DrEricDing) October 1, 2021

Trombose e trombocitopenia imune induzidas por vacina: resumo da diretriz NICE.

4 Out, 2021 | 10:36h

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance – The BMJ

Diretriz original: NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Conteúdos relacionados:

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

Triagem de terapia intensiva sob uma excepcional escassez de recursos.

4 Out, 2021 | 10:26h

Intensive care triage under exceptional resource scarcity – Swiss Medical Weekly

Campanha de sobrevivência à sepse: diretrizes internacionais para o tratamento da sepse e do choque séptico 2021.

4 Out, 2021 | 10:23h

Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 – Intensive Care Medicine

Estudo randomizado | Angiografia coronariana por tomografia computadorizada precoce em pacientes com suspeita de síndrome coronariana aguda não melhorou o desfecho clínico de 1 ano.

4 Out, 2021 | 10:17h

Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial – The BMJ

Comentário no Twitter

In this RCT, early CT coronary angiography in the emergency department for patients with suspected / provisional diagnosis of acute coronary syndrome had no effect on rate of death or subsequent non-fatal #heartattack at 1 year.@bmj_latest #Wondrmedical https://t.co/usNKEGPDa4

— Prof Chris P Gale (@cpgale3) October 1, 2021

Revisão | Cuidados de saúde oral para pacientes criticamente doentes.

4 Out, 2021 | 09:38h

Oral health care for the critically ill: a narrative review – Critical Care

Registro internacional mostra que a mortalidade após uso de ECMO em pacientes com COVID-19 piorou em 2020.

1 Out, 2021 | 22:06h

Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry – The Lancet

Comentários:

ECMO in COVID-19: do not blame the tool – The Lancet

ECMO life support offers sickest COVID-19 patients a chance to survive, but a slimmer one than once thought – Michigan Medicine – University of Michigan

Comentário no Twitter (fio – clique para saber mais)

New study indicates mortality after ECMO for patients with #COVID19 worsened during 2020, and duration of ECMO support increased.

Continued surveillance of ECMO outcomes in #COVID19 is needed, authors suggest: https://t.co/9Yq7lYkVIC

(1/2) @ELSOOrg pic.twitter.com/Rcz1TZ7eGG

— The Lancet (@TheLancet) September 30, 2021

Mais uma metanálise sugere que anticoagulação profilática é a melhor opção para pacientes hospitalizados com Covid-19.

1 Out, 2021 | 22:02h

A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients – Frontiers in Pharmacology

Conteúdo relacionado: M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.